Extensive Comments To GSK1349572 In Bit By Bit Order
1��1.3, P=0.001). The proportion of �� ��3-PUFA in patients with poor outcome was significantly lower than that in patients with good outcome (10.8��1.6 vs. 12.2��1.9, P=0.001) (Table 1). Table 1 Demographic data and comparison of clinical data according to functional outcome Association of fatty acid composition with stroke severity on admission, recurrent stroke, and functional outcome After adjusting for factors including age, sex, and variables with PSelleckchem BMS-354825 sensitivity C-reactive protein, fasting glucose, 16:0 palmitic acid, and �� saturated fatty acids), lower proportion of EPA and DHA were independently associated with stroke severity on admission (��: -0.751, standard error (SE): 0.376, P=0.048 for EPA, ��: -0.610, SE: 0.215, P=0.005 for DHA). Moreover, the �� ��3-PUFA was significantly associated with stroke severity on admission (��: -0.462, SE: 0.156, P=0.004) (Table 2) (Fig. 1). Considering stroke subtypes, DHA and �� ��3-PUFA were correlated with stroke severity on admission, in both large artery atherosclerosis (even though it showed tendency for �� ��3-PUFA, P=0.065) and small vessel occlusion, however EPA (Supplementary Table 2) did not appear to be correlated in multivariate linear regression analysis. There were six recurrent stroke cases and events, and EPA was relatively lower in the recurrent group compared to the non-recurrent group (1.6��0.2 vs. 2.0��0.7, P=0.006). www.selleckchem.com/products/s-gsk1349572.html However, the proportions of DHA and �� ��3-PUFAs were not different between the two groups (Supplementary Table 3). Figure 1 Plots of the National Institutes of Health Stroke Scale (NIHSS) score for 20:5 ��3 eicosapentaenoic SAR1B acid (A), 22:6 ��3 docosahexaenoic acid (B), and ��3-polyunsaturated fatty acids (C). Table 2 The relationship between fatty acids composition and stroke severity on admission (National Institute of Health Stroke Scale score)* Regarding functional outcome at three months after index stroke, a lower proportion of DHA (odds ratio (OR): 0.20, 95% confidence interval (CI): 0.04-0.88, P=0.033) and �� ��3-PUFA (OR: 0.22, 95% CI: 0.05-0.84, P=0.028) showed a significant relationship with poor functional outcome. However, EPA was not independently associated with poor functional outcome (OR: 0.60, 95% CI: 0.12 -2.93, P=0.533) in multivariate analysis after adjusting for age, sex, smoking status, NIHSS score, stroke subtypes, or 16:0 palmitic acid (Table 3). Considering stroke subtypes, a lower proportion of DHA and �� ��3-PUFAs was independently associated with poor functional outcome in both the large artery atherosclerosis subtype (OR: 0.62, 95% CI: 0.42-0.93, P=0.023 for DHA, OR: 0.65, 95% CI: 0.47-0.90, P=0.011 for �� ��3-PUFA) and the small vessel occlusion subtype (OR: 0.49, 95% CI: 0.28-0.85, P=0.012 for DHA, OR: 0.64, 95% CI: 0.42-0.98, P=0.044 for �� ��3-PUFA) (Supplementary Table 4).
